Werner Siegmund

Werner Siegmund

Auto-generated profile, based on publicly available information

Werner Siegmund

Department of Clinical Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald, Greifswald, Germany

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2002 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
WSWerner Siegmund
Werner Siegmund
KLKaren Ludwig
Karen Ludwig
TGThomas Giessmann
Thomas Giessmann
PDPeter Dazert
Peter Dazert
ESEike Schroeder
Eike Schroeder
ICIngolf Cascorbi
Ingolf Cascorbi
Background and objectives: A single‐nucleotide polymorphism (SNP) of the human multidrug‐resistance gene in wobble position of exon 26 reportedly predicts expression and function of P‐glycoprotein in human enterocytes and lymphocytes. Several other allelic variants of MDR1 have been identified, some of which lead to amino acid exchange with as yet unknown functional relevance.Methods: In healthy white volunteers, we investigated the influence of the hereditary variants C3435T in exon 26 and G2677T/A (Ala893Ser/Thr) in exon 21 and the influence of 7 frequent or putative functional SNPs on duodenal MDR1 messenger ribonucleic acid (n = 32) and immunoreactive P‐glycoprotein (n = 37) expression. Moreover, the disposition of the probe drug talinolol was evaluated in 55 subjects after oral administration (100 mg) and in 23 subjects after intravenous administration(30 mg).Results: Duodenal MDR1 messenger ribonucleic acid and P‐glycoprotein, as assessed by real‐time polymerase chain reaction (TaqMan) and immunostaining, were not influenced by any MDR1 polymorphism studied. Talinolol disposition was not affected by the exon 26 mutation C3435T. In carriers of the TT/TA variants of G2677T/A, the area under the serum concentration‐time curve values of oral talinolol were slightly but significantly elevated compared with those in carriers of at least 1 wild‐type allele (P < .05, Kruskal‐Wallis test; P = .014, Mann‐Whitney U test). However, multiple comparisons with combinations of putative functional SNPs did not confirm a significant influence of the MDR1 genotype on talinolol disposition.Conclusions: We did not identify any influence of MDR1 genotypes on duodenal expression of P‐glycoprotein and disposition of talinolol in humans.Clinical Pharmacology & Therapeutics (2002) 72, 572–583; doi: 10.1067/mcp.2002.127739

1 September 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JPJette Peters
Jette Peters
WBWiebke Block
Wiebke Block
SOStefan Oswald
Stefan Oswald
JFJohanna Freyer
Johanna Freyer
MGMarkus Grube
Markus Grube
WSWerner Siegmund
Werner Siegmund
The delivery of clarithromycin (CRL) to its site of action in bronchial/alveolar epithelial cells (EC), bronchial epithelial lining fluid (ELF), and bronchoalveolar lavage cells (BALC) may be influenced by CYP3A4 and the drug transporters, ATP-binding cassette (ABC) B1 and ABCC2 and organic anion-transporting polypeptides (OATPs), which can be modulated and/or up-regulated via the nuclear pregnane X receptor (PXR) by rifampicin (RIF). Therefore, we evaluated the disposition and pulmonary distribution of CLR (7.5 mg/kg b.i.d., 21 days) and expression of ABCB1, ABCC2, OATP1A2, and OATP2B1 in EC and BALC before and after comedication of RIF (10 mg/kg b.i.d., 11 days) in nine healthy foals (41–61 days, 115–159 kg) in which the genetic homology of drug transporters is close to that of their human analogs. After RIF comedication, relative bioavailability of CLR decreased by more than 90%. Concentrations in plasma (29.8 ± 26.3 versus 462 ± 368 ng/ml), ELF (0.69 ± 0.66 versus 9.49 ± 6.12 μg/ml), and BALC (10.2 ± 10.2 μg/ml 264 ± 375 μg/ml; all P < 0.05) were lowered drastically, whereas levels of the metabolite 14-hydroxyclarithromycin were not elevated despite higher 4β-hydroxycholesterol/cholesterol plasma concentration ratio, a surrogate for CYP3A4 induction. In the presence of CLR, ABCC2 and PXR mRNA contents were significantly and coordinately (r2 = 0.664, P < 0.001) reduced in BALC after RIF. In EC, mRNA expression of OATP1A2 increased but that of OATP2B1 decreased (both P < 0.05). RIF interrupts oral absorption and decreases CRL plasma levels below the minimal inhibitory concentration for eradication of Rhodococcus equi. Evidence that RIF influences the cellular uptake of CLR in bronchial cells and the PXR expression in BALC in the presence of high CLR concentrations exists.

1 January 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HGHans J Grabe
Hans J Grabe
HAHeinrich Assel
Heinrich Assel
TBThomas Bahls
Thomas Bahls
MDMarcus Dörr
Marcus Dörr
KEKarlhans Endlich
Karlhans Endlich
HKHeyo K Kroemer
Heyo K Kroemer
Individualized Medicine aims at providing optimal treatment for an individual patient at a given time based on his specific genetic and molecular characteristics. This requires excellent clinical stratification of patients as well as the availability of genomic data and biomarkers as prerequisites for the development of novel diagnostic tools and therapeutic strategies. The University Medicine Greifswald, Germany, has launched the “Greifswald Approach to Individualized Medicine” (GANI_MED) project to address major challenges of Individualized Medicine. Herein, we describe the implementation of the scientific and clinical infrastructure that allows future translation of findings relevant to Individualized Medicine into clinical practice. Clinical patient cohorts (N > 5,000) with an emphasis on metabolic and cardiovascular diseases are being established following a standardized protocol for the assessment of medical history, laboratory biomarkers, and the collection of various biosamples for bio-banking purposes. A multi-omics based biomarker assessment including genome-wide genotyping, transcriptome, metabolome, and proteome analyses complements the multi-level approach of GANI_MED. Comparisons with the general background population as characterized by our Study of Health in Pomerania (SHIP) are performed. A central data management structure has been implemented to capture and integrate all relevant clinical data for research purposes. Ethical research projects on informed consent procedures, reporting of incidental findings, and economic evaluations were launched in parallel.

4 November 2006 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SOStefan Oswald
Stefan Oswald
TGThomas Giessmann
Thomas Giessmann
DLDieter Luetjohann
Dieter Luetjohann
DWDanilo Wegner
Danilo Wegner
DRDieter Rosskopf
Dieter Rosskopf
WSWerner Siegmund
Werner Siegmund

11 September 2002 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
WSWerner Siegmund
Werner Siegmund
SAStephan Altmannsberger
Stephan Altmannsberger
APAndrea Paneitz
Andrea Paneitz
UHUte Hecker
Ute Hecker
MZMichael Zschiesche
Michael Zschiesche
HKHeyo K. Kroemer
Heyo K. Kroemer
Objective Thyroid function alters the pharmacokinetics of many drugs; one example is the cardiac glycoside digoxin. Because digoxin disposition is affected by intestinal expression of P‐glycoprotein, we hypothesized that thyroid hormones may regulate P‐glycoprotein and influence disposition of P‐glycoprotein substrates. Methods Duodenal expression of P‐glycoprotein measured by reverse transcriptase‐polymerase chain reaction of MDR1 messenger ribonucleic acid (mRNA) and by immunohistochemical examination was studied in 8 healthy volunteers (4 men and 4 women; age range, 22‐29 years; body weight, 59–89 kg) before and after coadministration with levothyroxine (200 μg orally for 17 days), which resulted in suppression of thyroid‐stimulating hormone. The pharmacokinetics of the P‐glycoprotein substrate talinolol was assessed after intravenous (30 mg) and oral (100 mg) administration. Results Duodenal MDR1 mRNA expression and immunoreactive P‐glycoprotein were increased 1.4‐fold (not significant; P = .078) and 3.8‐fold (P < .01), respectively, after administration of levothyroxine. The changes in P‐glycoprotein expression were associated with minor alterations in talinolol half‐life after both oral and intravenous administration. Conclusions Expression of intestinal P‐glycoprotein in humans appears to be influenced by thyroid hormones. The functional consequences need to be addressed in patients with hyperthyroidism. Clinical Pharmacology & Therapeutics (2002) 72, 256–264; doi: 10.1067/mcp.2002.126706

24 January 2006 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
ABAnnika Bernsdorf
Annika Bernsdorf
TGThomas Giessmann
Thomas Giessmann
CMChristiane Modess
Christiane Modess
DWDanilo Wegner
Danilo Wegner
SIStefanie Igelbrink
Stefanie Igelbrink
WSWerner Siegmund
Werner Siegmund
Aims: To evaluate whether simvastatin influences (i) the intestinal expression of P‐glycoprotein (P‐gp) and MRP2, and (ii) the disposition of the β1‐selective blocker talinolol, a substrate of these transporter proteins.Methods: The disposition of talinolol after intravenous (30 mg) and single or repeated oral administration (100 mg daily) was monitored before and after chronic treatment with simvastatin (40 mg daily) in 18 healthy subjects (10 males, eight females, body mass index 19.0–27.0 kg m−2) genotyped for ABCB1, ABCC2 and SLCO1B1 polymorphisms. The steady‐state pharmacokinetics of simvastatin was evaluated before and after repeated oral talinolol administration. The duodenal expression of ABCB1 and ABCC2 mRNA before and after simvastatin treatment was quantified using real‐time reverse transcriptase‐polymerase chain reaction (TaqMan®).Results: Simvastatin did not influence the expression of duodenal ABCB1 and ABCC2. There was no significant pharmacokinetic interaction between simvastatin and talinolol. Duodenal ABCB1 mRNA content was significantly correlated with the AUC0–∞ (r = 0.627, P = 0.039) and Cmax (r = 0.718, P = 0.013) of oral talinolol. The ABCB1 and ABCC2 gene polymorphisms did not influence simvastatin and talinolol disposition. The half‐life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild‐type SLCO1B1*1a/*1a genotype (12.2 ± 1.6 h vs. 14.5 ± 1.4 h, P = 0.01).Conclusions: Simvastatin does not influence the intestinal expression of P‐gp and MRP2 in man. There was no pharmacokinetic interaction between talinolol and simvastatin during their chronic co‐administration to healthy subjects.